Select Language
TBNK Related antibody
Product Inquiry
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mim8 | Mim8; NN7769; NNC0365-3769; NN-7769 | Phase 3 Clinical | Novo Nordisk A/S | Hemophilia A | Details |
| Eptacog Alfa Biosimilar(Aryogen Pharmed) | Phase 3 Clinical | Aryogen Pharmed Co | Hemophilia A; Factor VII Deficiency | Details | |
| CT-001 (Coagulant Therapeutics) | CT-001; CT001 | Phase 3 Clinical | Coagulant Therapeutics Corp | Pain; Postpartum Hemorrhage | Details |
| Human prothrombin complex concentrate (Sichuan Yuanda Shuyang Pharmaceutical) | Phase 3 Clinical | Blood Coagulation Disorders | Details | ||
| BBM-H901 | BBM-H901 | Phase 3 Clinical | Belef BioMed (Shanghai) Co Ltd | Hemophilia B | Details |
| Human prothrombin complex concentrate (Harbin Shiheng Bioengineering Pharmaceutical) | Phase 3 Clinical | Harbin Pacific Biopharmaceutical Co Ltd | Hemophilia B | Details | |
| Human prothrombin complex (Lanzhou Lansheng Blood Products) | Phase 3 Clinical | Lanzhou Lansheng Blood Products Co Ltd | Hemophilia B | Details | |
| Recombinant human coagulation factor VIIa (Chengdu Rongsheng Pharmaceuticals) | Phase 3 Clinical | Chengdu Rongsheng Pharmaceuticals Co Ltd | Hemophilia A | Details | |
| Human prothrombin complex(Hunan Ziguang Huhan Nanyue Pharmaceutical) | Phase 3 Clinical | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Hemophilia B | Details | |
| aPCC-emicizumab | Phase 3 Clinical | Emory University | Hemophilia A | Details | |
| Dalcinonacog alfa | ISU304; ISU-304; CB-2679d | Phase 2 Clinical | Catalyst Bioscience | Hemophilia B | Details |
| BAX-335 | BAX-335; AskBio-009 | Phase 2 Clinical | Glaxosmithkline Plc, Asklepios BioPharmaceutical Inc, Bayer AG | Hemophilia B | Details |
| Factor VIIa-CTP | MOD-5014; MOD-5017; OPK88005 | Phase 2 Clinical | Opko Health Inc, Prolor Biotech | Blood Coagulation Disorders, Inherited; Hemophilia A; Hemophilia B | Details |
| FT-004 | FT-004; FT004 | Phase 2 Clinical | Frontera Therapeutics (Shanghai) Co Ltd | Hematologic Diseases; Hemophilia B | Details |
| ZS-801 | ZS801; ZS-801 | Phase 2 Clinical | Hemophilia B | Details | |
| ANB-002 | ANB-2; ANB-002 | Phase 2 Clinical | BIOCAD JSC | Hemophilia B | Details |
| VGB-R04 | VGB-R04 | Phase 2 Clinical | Shanghai Vitalgen BioPharma Co Ltd | Hemophilia B | Details |
| Eptacog alfa biosimilar (Valin Technologies) | Phase 1 Clinical | Valin Technologies | Hemophilia A | Details | |
| Marzeptacog alfa | CB-813; CB-813d; PF-5280602; PF-05280602 | Phase 1 Clinical | Catalyst | Hemophilia A; Hemophilia B | Details |
| AAV2-hFIX16 | AAV2-hFIX16 | Phase 1 Clinical | Spark Therapeutics Inc | Hemophilia B | Details |
| SS-327 | GenSciences-327; 注射用培重组人凝血因子IX-Fc融合蛋白; SS327 | Phase 1 Clinical | Zhengzhou Shengsi Biotechnology Co Ltd, Furen Pharmaceutical Group Co Ltd | Hemophilia B | Details |
| JWK-004 | JWK004; JWK-004 | Phase 1 Clinical | Chengdu Genevector Therapeutics Co Ltd | Hemophilia B | Details |
| Human prothrombin complex (National Drug Group Wuhan Blood) | Phase 1 Clinical | Hemorrhage | Details | ||
| SR-604 | SR-604; SR604 | Phase 1 Clinical | Shanghai Raas Blood Products Co Ltd | Hemophilia A; Hemophilia B; Hemorrhage | Details |
| YUVA-GT-F901 | YUVA-GT-F901 | Phase 1 Clinical | Novartis Pharma Ag | Hemophilia B | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-inhibitor coagulant complex (Baxalta) | Approved | Baxalta Incorporated | Feiba, Prothromplex TOTAL | United States | Hemophilia A; Hemophilia B | Baxalta Incorporated | 1979-12-21 | Blood Coagulation Disorders; Blood Coagulation Disorders, Inherited; Hemophilia A; Hemophilia B; Cardiovascular Diseases | Details | |
| Human prothrombin complex (Nanyue Biopharming) | Approved | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | 2019-09-05 | Hemophilia B; Hemorrhage | Details | ||
| Eptacog alfa (Novo Nordisk) | NN-007 | Approved | Novo Nordisk A/S | NiaStase, NovoSeven, 诺其 | EU | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Novo Nordisk A/S | 1996-02-23 | Cerebral Hemorrhage; Spinal Diseases; Hemophilia A; Hemophilia B; Fibrosis; Hemorrhage; Stroke; Postpartum Hemorrhage; Factor VII Deficiency; Severe Dengue; Burns; Wounds and Injuries; Blood Loss, Surgical; Thrombasthenia; Acquired hemophilia | Details |
| Etranacogene dezaparvovec | AAV5-hFIX; AMT-061; CSL-222; AMT-060 | Approved | University College London, Uniqure Biopharma Bv | HEMGENIX | United States | Hemophilia B | Csl Behring | 2022-11-22 | Hemophilia B | Details |
| Human prothrombin complex (CSL Behring) | BE-1116 | Approved | Csl Behring Llc | Kcentra, Beriplex, Confidex | Blood Coagulation Disorders; Coagulation Protein Disorders; Heart Failure; Heart Diseases; Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Wounds and Injuries | Details | ||||
| Freeze-dried activated human blood coagulation factor Ⅶ concentrate containing factor Ⅹ (Kaketsuken/KM Biologics) | MC-710 | Approved | Kaketsuken | Byclot | Japan | Hemophilia A | null | 2014-07-04 | Hemophilia A | Details |
| Human prothrombin complex concentrate (Guizhou Taibang Biological Products) | Approved | Guizhou Taibang Biological Products Co Ltd | Mainland China | Hypoprothrombinemias | Guizhou Taibang Biological Products Co Ltd | 2013-07-31 | Hypoprothrombinemias | Details | ||
| Prothrombinex-VF (CSL Behring) | Approved | Csl Behring Llc | Australia | Hemorrhage | Csl Behring Llc | 2014-10-01 | Hemorrhage | Details | ||
| Fidanacogene elaparvovec | PF-06838435; SPK-9001 | Approved | The Children'S Hospital Of Philadelphia | BEQVEZ, DURVEQTIX | Canada | Hemophilia B | Pfizer Inc | 2024-01-03 | Hemophilia A; Hemophilia B | Details |
| Prothrombin complex concentrate (Sanquin) | Approved | Sanquin Plasma Products Bv | Cofact | Hemorrhage | Sanquin Plasma Products Bv | 2007-11-01 | Hemorrhage | Details | ||
| Emicizumab | RG-6013; ACE-910; RO-5534262 | Approved | Genentech Inc, Chugai Pharmaceutical Co Ltd | 舒友立乐, Hemlibra | United States | Hemophilia A | Genentech Inc | 2017-11-16 | Hemophilia A; Hemorrhage; von Willebrand Disease, Type 3 | Details |
| Eptacog alfa biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Iran | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Aryogen Biopharma | 2014-01-01 | Hemophilia A; Hemophilia B; Factor VII Deficiency; Thrombasthenia | Details | ||
| Factor IX complex (Grifols) | Approved | Grifols Sa | Profilnine | United States | Hemophilia B | null | 1981-07-21 | Intracranial Hemorrhages; Hemophilia B | Details | |
| Eptacog beta | LR-769; rhFVIIa | Approved | Lfb Biotechnologies Sas, Revo Biologics Inc | Sevenfact | United States | Hemophilia A; Hemophilia B | Lfb Biotechnologies Sas | 2020-04-01 | Hemophilia A; Hemophilia B | Details |
| Human prothrombin complex (Octapharma) | Approved | Octapharma | Ocplex, Octaplex, Pronativ | Germany | Hemorrhage | Octapharma | 2003-03-14 | Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Eptacog alfa biosimilar (International Biotech Center Generium) | GNR-001 | Approved | International Biotech Center Generium | Russian Federation | Hemophilia A | International Biotech Center Generium | 2015-01-01 | Hemophilia A | Details | |
| Human prothrombin complex (LFB) | Approved | Lfb Biotechnologies Sas | KANOKAD | France | Hemorrhage | Lfb Biotechnologies Sas | 2008-09-01 | Hemorrhage | Details | |
| Human prothrombin complex (Tonrol Biopharmaceuticals) | Approved | Tonrol Bio-Pharmaceutical Co Ltd | ProthoRAAS | Mainland China | Hemorrhage | Shanghai Raas Blood Products Co Ltd | 1996-01-01 | Hemophilia B; Hemorrhage | Details | |
| Human prothrombin complex (Guangdong Shuanglin) | Approved | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia B | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | 2023-05-12 | Hemophilia B | Details | ||
| Human prothrombin complex (Shanghai Xinxing) | Approved | Mainland China | Hemorrhage | Shanghai Xinxing Medicine Co Ltd | 1997-01-01 | Hemorrhage | Details | |||
| Human prothrombin complex (Sinopharm Shanghai Plasma) | Approved | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | Mainland China | Hemorrhage | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
| Human prothrombin complex (Boya Bio-Pharmaceutical) | Approved | Boya Bio-Pharmaceutical Group Co Ltd | Mainland China | Hemorrhage | Boya Bio-Pharmaceutical Group Co Ltd | 2020-12-02 | Hemophilia B; Hemorrhage | Details | ||
| Human prothrombin complex (Guangdong Wellen) | Approved | Guangdong Wellen Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Guangdong Wellen Pharmaceutical Co Ltd | 2020-10-21 | Hemophilia B; Hemorrhage | Details | ||
| Factor IX (Octapharma ) | Approved | Octapharma | Octanine F 100 I.E./ml Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, OCTANINE F 500 UI pulbere şi solvent pentru soluţie perfuzabilă, octanine 500TV milteliai ir tirpiklis injekciniam tirpalui, Octanine 100 IU/ml, OCTANINE, OCTANINE 500 NE por és oldószer oldatos injekcióhoz, Octanine 500 SV pulveris un šķīdinātājs injekciju šķīduma pagatavošanai, Octanine F 500 | EU | Hemophilia B | Octapharma | 2001-12-23 | Hemophilia B | Details | |
| Human prothrombin complex(Hebei Daan Pharmaceutical) | Approved | Hebei Daan Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hebei Daan Pharmaceutical Co Ltd | 2020-01-01 | Hemophilia B; Hemorrhage | Details | ||
| Prothrombin complex concentrat (Taibang Biological Products) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Hemorrhage | Shandong Taibang Biological Products Co Ltd | 2014-09-30 | Hemorrhage; Antithrombin III Deficiency | Details | ||
| Human prothrombin complex (Hualan Biological Engineering) | Approved | Hualan Genetic Engineering Co Ltd | Mainland China | Blood Coagulation Disorders; Factor X Deficiency | Hualan Biological Engineering Inc | 1999-01-01 | Blood Coagulation Disorders; Hemophilia B; Factor X Deficiency | Details | ||
| Human prothrombin complex concentrate (Shanxi Kangbao Biological Products) | Approved | Shanxi Kangbao Biological Product Co Ltd | Mainland China | Hemorrhage | Shanxi Kangbao Biological Product Co Ltd | 2019-09-17 | Hemophilia B; Hemorrhage | Details |
- Product Inquiry
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호